KANSAS CITY, Kan. (October 17, 2015) – Ryan Reed finished fourth on Friday night in the No. 38 Lilly Diabetes Lira Motorsports Ford Fusion in the ARCA Racing Series presented by Menards season finale at Kansas Speedway.
“I really wanted to get a third win for the Lira Motorsports team at Kansas,” said Reed. “The car was great when we ended practice and then just was bottoming out in qualifying and during the race. I have enjoyed working with this team this year and cant thank Carlos Lira and Jack Roush enough for the opportunity.”
Reed started the 99-lap event from the 12th position on Friday evening and was up to the fourth position by the end of the first lap. With sparks flying from the bottom of the No. 38 machine, Reed continued to gain positions despite the car bottoming out on the track. By Lap 6, he had advanced to the second position.
The first caution of the race came on Lap 10. The sparks that had previously coming from underneath the car had subsided as the tire pressure was building. Reed reported that the car was still bottoming out a bit. The team did not pit under the caution, leaving Reed in the second position for the following restart on Lap 15.
Reed took the lead on Lap 16 and held onto it until the Lap 25 caution flag. The team pitted for a track bar adjustment, four tires and fuel. Reed received a penalty for speeding on pit road, relegating him to 17th for the restart on Lap 32.
The caution was displayed again on Lap 37 while Reed was running 10th. The team pitted for fuel only on Lap 43. After restarting 10th on Lap 47, Reed had raced his way up to the fourth position by Lap 50.
The caution was displayed again on Lap 67 as Reed ran in the seventh position. The team pitted two laps later under caution for fresh tires, fuel and to reverse the previous track bar adjustment. Reed restarted eighth with 24 laps to go in the race.
With 15 laps to go, Reed was up to the fourth position. The two time ARCA Racing Series winner maintained fourth as the checkered flag flew on the 2015 season.
About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a broad and growing product portfolio and a continued determination to provide real solutions—from medicines to support programs and more — we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.com or follow us on Twitter: @LillyDiabetes.
